On (b)(6) 2016 zeltiq was notified that a female patient had developed blistering and pigment changes post treatment.The patient was treated on (b)(6) 2016 to the submental area using the coolmini applicator.On (b)(6) 2017 zeltiq was informed that the patient had been prescribed triluma topical cream to address pigmentary changes as an intervention measure, making this event reportable.Preexisting medical history of the patient was not able to be obtained by the time of this report.A follow-up report will be made to the agency if and when new information is received about this case.
|